News Headlines Article

Pharmaceutical industry defends ‘pay-for-delay’ deals
Los Angeles Times

Brand-name drug companies and their generic rivals spend so much time and money attacking each other — in court, in Congress, and everywhere else lawyers and lobbyists do battle — that when they land on the same side of an issue it’s a good guess that the consumer is getting whacked.

Lately they’ve rolled out the big guns in defense of a practice that looks very much like collusion. And according to the Federal Trade Commission, it costs consumers and government agencies billions of dollars a year.